Psychiatry

Economic Burden of Schizophrenia

A snapshot into the cost of illness in schizophrenia. Learn about the impact of nonadherence on hospital readmission rates, cost burden of relapses, and excess direct health care costs for patients diagnosed with schizophrenia.

Quality Metrics Tool for Schizophrenia

Review Healthcare Effectiveness Data and Information Set (HEDIS), National Quality Forum (NQF) endorsed, and Centers for Medicare & Medicaid Services (CMS) Star Ratings measures for schizophrenia all in one easy-to-use tool.

DSM-5-TR Diagnostic Criteria for Schizophrenia

Review the latest Diagnostic And Statistical Manual Of Mental Disorders-5 (DSM-5-TR) Diagnostic Criteria for Schizophrenia

ICD-10 Diagnostic Codes for Schizophrenia

Update your awareness of the International Classification Of Disease-10-Clinical Modification (ICD-10-CM) Chart diagnostic codes for Schizophrenia

Mental Health Parity Laws (Federal and State) 2022

A comprehensive guide summarizing the current federal and state mental health parity laws on a state-by-state basis directly from state statutes covering health care and insurance. You can easily navigate to the laws in your state using the directory provided in this guide.
References
*Based on a claims-based analysis of 8985 patients with newly diagnosed and chronic schizophrenia. Individuals had ≥2 claims with a diagnosis code for schizophrenia on separate dates during 2011. The mean cost per patient was compared to the costs in a demographically adjusted nonschizophrenic population.
  1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76.
  2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2022.
  3. World Health Organization. Schizophrenia. Accessed May 26, 2022. https://www.who.int/news-room/fact-sheets/detail/schizophrenia
  4. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Ann Rev Clin Psychol. 2014;10:425-438.
  5. Fitch K, et al. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits. 2014;7(1):18-26.